C&S Partners advises Dr. Lal PathLabs on acquiring 70% stake in SN Genelab

SN Genelab is a leading genomics focused diagnostic company.

Deepali Chandhoke, Saurabh Tiwari

Published on:

04 Nov 2026, 6:44 am

1 min read

Listen to this article

Dr. Lal PathLabs Limited has acquired a 70% stake in SN Genelab Private Limited.

C&S Partners advised Dr. Lal PathLabs on this acquisition. The Firm led the preparation and advice on transaction documents, negotiations and related advisory on corporate & employment law matters.

The transaction team consisted of Saurabh Tiwari (Partner), Arya Sharma (Associate), and Aditya Singh (Associate).

Deepali Chandhoke (Senior Partner) provided strategic inputs on employment law issues.

SN Genelab is a leading genomics focused diagnostic company, providing services in areas of oncology, rare diseases, infectious diseases and reproductive health.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

C&S Partners